+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
ID07810777

Evaluating the Safety and Efficacy of PRA-216 Compared to Placebo in Adults with Moderate to Severe Atopic Dermatitis A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study

Led by Prana Therapies Inc · Updated on 2026-10-28

39

Participants Needed

9

Research Sites

32 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, pharmacokinetics, and immune response of PRA-216 compared to a placebo in adults with moderate to severe Atopic Dermatitis AD. This Phase 2 study includes patients whose AD is not well controlled by topical corticosteroids or who have had adverse reactions or cannot use such medications. Approximately 39 participants will take part in this multicenter, randomized, double-blind, placebo-controlled trial. Participants will be randomly assigned in a 21 ratio to receive either PRA-216 or a matching placebo via subcutaneous injections. Each participant will receive four injections during the study period. The study is designed to observe and compare the effects of PRA-216 and placebo on AD symptoms and safety measures. Throughout the study, participants will attend multiple visits for monitoring. Researchers will assess treatment-emergent adverse events and serious adverse events for up to 28 weeks. They will also evaluate clinical responses using measures such as EASI-75 and EASI-90 scores for up to 24 weeks. Pharmacokinetics parameters like Tmax, AUC, and Cmax, as well as immunogenicity, will be monitored. The total study duration extends to May 2028.

CONDITIONS

Brief Title

PRA-216 Atopic Dermatitis Safety and Efficacy Study

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here